Mesenchymal stem cell–derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo

Authors

  • Daan van Poll,

    1. Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School and Shriners Hospitals for Children, Boston, MA
    2. Department of Surgery, University Medical Center, University of Utrecht, Utrecht, The Netherlands
    Search for more papers by this author
    • These authors contributed equally to this study.

  • Biju Parekkadan,

    1. Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School and Shriners Hospitals for Children, Boston, MA
    2. Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA
    Search for more papers by this author
    • These authors contributed equally to this study.

  • Cheul H. Cho,

    1. Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School and Shriners Hospitals for Children, Boston, MA
    Search for more papers by this author
  • François Berthiaume,

    1. Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School and Shriners Hospitals for Children, Boston, MA
    Search for more papers by this author
  • Yaakov Nahmias,

    1. Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School and Shriners Hospitals for Children, Boston, MA
    Search for more papers by this author
  • Arno W. Tilles,

    1. Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School and Shriners Hospitals for Children, Boston, MA
    Search for more papers by this author
  • Martin L. Yarmush

    Corresponding author
    1. Center for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School and Shriners Hospitals for Children, Boston, MA
    2. Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA
    • 51 Blossom Street, Boston, MA 02114
    Search for more papers by this author
    • fax: 617-371-4950.


  • Potential conflict of interest: Nothing to report.

Abstract

Orthotopic liver transplantation is the only proven effective treatment for fulminant hepatic failure (FHF), but its use is limited because of organ donor shortage, associated high costs, and the requirement for lifelong immunosuppression. FHF is usually accompanied by massive hepatocellular death with compensatory liver regeneration that fails to meet the cellular losses. Therefore, therapy aimed at inhibiting cell death and stimulating endogenous repair pathways could offer major benefits in the treatment of FHF. Recent studies have demonstrated that mesenchymal stem cell (MSC) therapy can prevent parenchymal cell loss and promote tissue repair in models of myocardial infarction, acute kidney failure, and stroke through the action of trophic secreted molecules. In this study, we investigated whether MSC therapy can protect the acutely injured liver and stimulate regeneration. In a D-galactosamine–induced rat model of acute liver injury, we show that systemic infusion of MSC-conditioned medium (MSC-CM) provides a significant survival benefit and prevents the release of liver injury biomarkers. Furthermore, MSC-CM therapy resulted in a 90% reduction of apoptotic hepatocellular death and a three-fold increment in the number of proliferating hepatocytes. This was accompanied by a dramatic increase in the expression levels of 10 genes known to be up-regulated during hepatocyte replication. Direct antiapoptotic and promitotic effects of MSC-CM on hepatocytes were demonstrated using in vitro assays. Conclusion: These data provide the first clear evidence that MSC-CM therapy provides trophic support to the injured liver by inhibiting hepatocellular death and stimulating regeneration, potentially creating new avenues for the treatment of FHF. (HEPATOLOGY 2008.)

Ancillary